Pfizer Inc. (NYSE:PFE) announced a quarterly dividend on Monday, December 14th, Market Beat.com reports. Investors of record on Friday, February 5th will be paid a dividend of 0.30 per share by the biopharmaceutical company on Wednesday, March 2nd. This represents a $1.20 annualized dividend and a dividend yield of 3.97%. The ex-dividend date is Wednesday, February 3rd. This is an increase from Pfizer’s previous quarterly dividend of $0.24.

PFE has been the subject of several research analyst reports. Jefferies Group lifted their target price on shares of Pfizer to $48.00 and gave the stock a “buy” rating in a report on Monday, December 7th. Barclays reissued a “neutral” rating and issued a $34.00 price objective on shares of Pfizer in a report on Tuesday, January 5th. Vetr raised shares of Pfizer from a “buy” rating to a “strong-buy” rating and set a $37.47 price objective for the company in a report on Tuesday, October 6th. Sanford C. Bernstein set a $41.00 price objective on shares of Pfizer and gave the company a “buy” rating in a report on Monday, November 23rd. Finally, Atlantic Securities set a $39.00 price objective on shares of Pfizer and gave the company a “buy” rating in a report on Wednesday, December 30th. Six research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $39.83.

Shares of Pfizer (NYSE:PFE) opened at 30.20 on Friday. The company has a market capitalization of $186.42 billion and a price-to-earnings ratio of 22.67. Pfizer has a 12-month low of $28.47 and a 12-month high of $36.46. The firm’s 50-day moving average is $31.61 and its 200-day moving average is $33.14.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, October 27th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, beating analysts’ consensus estimates of $0.51 by $0.09. The company earned $12.10 billion during the quarter, compared to analysts’ expectations of $11.56 billion. During the same period in the prior year, the business earned $0.57 earnings per share. The company’s revenue for the quarter was down 2.2% compared to the same quarter last year. On average, equities analysts predict that Pfizer will post $2.19 EPS for the current year.

Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its products include Lyrica, the Prevnar family of products, Enbrel, Celebrex, Lipitor, Viagra, Zyvox, Sutent, EpiPen, Toviaz, Tygacil, Rapamune, Xalkori, Inlyta, Norvasc, BeneFIX, Genotropin and Enbrel, among others. It operates in three segments: Global Innovative Pharmaceutical segment (NYSE:PFE), Global Vaccines, Oncology and Consumer Healthcare segment (VOC) and Global Established Pharmaceutical segment (GEP). GIP is focused on developing, registering and commercializing medications in therapeutic areas, such as inflammation, cardiovascular/metabolic, neuroscience and pain, rare diseases and women’s/men’s health. VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. GEP includes its sterile injectable products and bio similar development portfolio. Its subsidiary is Hospira, Inc.

12 Month Chart for NYSE:PFE

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.